97202 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells Lung
Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
#302Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
#303Antibodies against CD73
#304TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODY
#305Enhancing the therapeutic activity of immune checkpoint inhibitor
#306Method of identifying anti-VISTA antibodies
#307Interferon therapy
#308COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS
#309Methods and materials for treating cancer
#310COMBINATION THERAPIES
#311USES OF ANTI-HER3 ANTIBODIES FOR TREATING CANCER
#312Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
#313Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
#314Antibodies for epidermal growth factor receptor 3 (HER3)
#315Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
#316Site specific HER2 antibody drug conjugates
#317FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
#318Compositions comprising a combination of nivolumab and ipilimumab
#319ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF
#320Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
#321ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS
#322Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
#323Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
#324Provasopressin antagonists and uses thereof
#325ANTIBODY DRUG CONJUGATES
#326Combination of CD95/CD95L inhibition and Cancer Immunotherapy
#327Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
#328GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND USE THEREOF
#329Human-mouse chimeric anti-CD147 antibody with non-fucosylated glycosylation
#330Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
#331Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
#332β-glucan methods and compositions that affect the tumor microenvironment
#333Anti human Notch4 antibody
#334Antibodies specifically binding to HER3
#335Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist
#336Compositions and methods for the diagnosis and treatment of tumor
#337Anti-malignant tumor agent
#338Anti-EGFR antibodies and antibody drug conjugates
#339Anti-vista antibodies and fragments
#340Therapeutic drug for malignant tumors
#341Humanized monoclonal antibodies and methods of use
#342Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
#343Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors
#344Mutated antibody of fully humanized HER2 antibody, and encoding gene and use thereof
#345Antibody therapeutics that bind CD147
#346Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#347COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER
#348Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#349Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#350Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#351Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
#352Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#353Method for treating cancer with an activated T lymphocyte that selectively recognizes a cancer cell consisting of specific peptide
#354Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#355Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#356Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#357(Anti-HER2 antibody)-drug conjugate
#358ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER
#359Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof
#360MULTIMERIC FC PROTEINS
#361Immunoactivating antigen-binding molecule
#362Antibody therapeutics that bind LAG3
#363Anti-HER3 antibody-drug conjugate
#364COMBINATION THERAPY COMPRISING ANTI-ANGIOGENESIS AGENTS AND OX40 BINDING AGONISTS
#365ANTI-NOTCH3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
#366Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#367Anti-metalloprotease antibody for diagnosis and treatment of cancers
#368METHODS OF TREATING HER2-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-HER2 ANTIBODIES
#369Antibody-drug conjugates and immunotoxins
#370Antibodies and immunoconjugates
#371PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS
#372Anti-DLL3 antibody drug conjugates for treating cancer
#373PROTEINS COMPRISING AMINO-TERMINAL PROXIMAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND CELL-TARGETING IMMUNOGLOBULIN-TYPE BINDING REGIONS
#374Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
#375PROSTATE-ASSOCIATED ANTIGENS AND VACCINE-BASED IMMUNOTHERAPY REGIMENS
#376Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
#377Use of pegylated IL-10 to treat cancer
#378Compositions and Methods for Diagnosing and Treating Cancer
#379Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes
#380ICOS binding proteins
#381Cancer therapy using CLDN6 target-directed antibodies in vivo
#382Antibodies against OX40 and uses thereof
#383THERAPEUTIC COMBINATIONS AND METHODS FOR TREATING NEOPLASIA
#384Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
#385Anticancer agent
#386Anti-HER2 antibody-drug conjugate
#387Anti-human TROP-2 antibody having an antitumor activity in vivo
#388Antibodies against claudin 18.2 useful in cancer diagnosis
#389Targeted therapy for small cell lung cancer
#390Targeting CLPTM1L for treatment and prevention of cancer
#391FRIZZLED-BINDING AGENTS AND USES THEREOF
#392MET-BINDING AGENTS AND USES THEREOF
#393Antigen binding proteins that bind ErbB3
#394Anti-CD40 antibodies
#395TUSC2 THERAPIES
#3965T4-TARGETED IMMUNOFUSION MOLECULE AND METHODS
#397Anti-EGFRvIII antibodies and uses thereof
#398NEUROPILIN ANTAGONISTS
#399COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY
#400Antibody-SN-38 immunoconjugates with a CL2A linker
#401Anti-TROP2 antibody-drug conjugate
#402Pharmaceutical composition for treatment and/or prevention of cancer
#403BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1
#404Anti-claudin antibodies and methods of use
#405Antigen binding proteins that bind CCR2
#406Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
#407Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof
#408Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
#409Antibody specific to the AIMP2-DX2
#410Anti-PD-L1 monoclonal antibodies and fragments thereof
#411Antibodies reactive with B7-H3 and uses thereof
#412Glycans as functional cancer targets and antibodies thereto
#413Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
#414Conjugated antibodies against LY75 for the treatment of cancer
#415Methods of treating cancers using PD-1 axis binding antagonists and taxanes
#416Antibodies specific for TROP-2 and their uses
#417Antibody-SN-38 immunoconjugates with a CL2A linker
#418Anti-DLL3 antibody
#419Anti-FGFR2/3 antibodies and methods using same
#420Binding molecules specific for HER3 and uses thereof
#421METHODS AND COMPOSITIONS FOR REGULATORY T-CELL ABLATION
#422Mesothelin domain-specific monoclonal antibodies and use thereof
#423TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR PROTEIN
#424LIPOSOME ENCAPSULATED AFFINITY DRUG
#425Anti-DLL3 antibody drug conjugates
#426Anti-B7-H1 antibodies for treating tumors
#427ICOS binding proteins
#428Antibodies to endoplasmin and their use
#429Anti-Ly6E antibodies and immunoconjugates and methods of use
#430ANTI-TISSUE FACTOR ANTIBODIES AND COMPOSITIONS
#431Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv
#432Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#433CANCER TREATMENT USING ANTIBODIES THAT BIND CELL SURFACE GRP78
#434COMBINED PHARMACEUTICAL COMPOSITION
#435Humanized monoclonal antibodies and methods of use
#436NOVEL ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER
#437MPS peptides and use thereof
#438ENGINEERED ANTI-DLL3 CONJUGATES AND METHODS OF USE
#439PROTEIN
#440Therapeutic Agent Comprising Humanized Anti-Epiregulin Antibody as Active Ingredient for Non-Small-Cell Lung Carcinoma Excluding Adenocarcinoma
#441Binding molecules specific for HER3 and uses thereof
#442Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
#443Methods of delivering DLL3 antibody drug conjugates
#444Diagnostic assays and kits for detection of folate receptor 1
#445BISPECIFIC ANTIBODIES
#446Antibodies against CD73
#447Anti-ErbB3 antibodies and uses thereof
#448Antibody molecules to PD-L1 and uses thereof
#449Compositions and methods for treatment and detection of cancers
#450Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#451Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies
#452Methods for enhancing anti-tumor antibody therapy
#453VISTA Antagonist and Methods of Use
#454Anti-DLL3 antibodies
#455Therapeutic peptides
#456THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS
#457Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#458CHARGE-ENGINEERED ANTIBODIES OR COMPOSITIONS OF PENETRATION-ENHANCED TARGETING PROTEINS AND METHODS OF USE
#459Anti-DLL3 antibody drug conjugates
#460Anti-RSPO2 antibodies and uses thereof
#461Anti-DLL3 antibody
#462Anti-DLL3 antibody drug conjugates
#463Recombinant human IgM-antibody effective against cancer cells
#464Anti-OX40 antibodies and methods of use
#465Antibodies to non-functional P2X7 receptor
#466Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#467Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#468Biomarker TFF1 for predicting effect of C-MET inhibitor
#469THERAPEUTIC AND DIAGNOSTIC TARGET
#470Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#471Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#472Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#473Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#474Multifunctional antibodies binding to EGFR and MET
#475Antibody against transporter and use thereof
#476LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same
#477Composition and method for diagnosis and immunotherapy of lung cancer
#478Anti-RSPO2 antibodies
#479Anti-RSPO1 antibodies and uses thereof
#480TUSC2 therapies
#481Anti-DLL3 antibody drug conjugates for treating cancer
#482Anti-DLL3 antibody drug conjugates
#483Anti-DLL3 antibodies
#484Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodies
#485Anti-DLL3 antibody drug conjugates and methods of use
#486Humanized and affinity-matured anti-c-Met antibody and uses thereof
#487Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
#488Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma
#489Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
#490Anti-DDR1 antibody having anti-tumor activity
#491ANTI-CD22 ANTIGEN BINDING MOLECULES TO TREAT LUNG CANCER AND PROSTATE CANCER
#492Monoclonal antibody against human non-small cell lung carcinoma and use thereof
#493Method for decreasing radioresistance and growth, metastasis and infiltration of cancer cells through regulating expression or activity of TM4SF4 in non-small cell lung cancer
#494Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#495Anti-tissue factor antibodies and compositions
#496Lung cancer differential marker
#497Cancer therapy using CLDN6 target-directed antibodies in vivo
#498Anti-ErbB3 antibodies and uses thereof
#499Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereof
#500COMPLEXES COMPRISING MHC CLASS I FUSION POLYPEPTIDES AND ANTIGEN-SPECIFIC ANTIBODIES AND METHODS OF USE
#501Anti-DLL3 antibody
#502Lung Tumor Markers and Methods of Use Thereof
#503Methods for enhancing anti-tumor antibody therapy
#504Antibodies reactive with B7-H3 and uses thereof
#505Pro104 Antibody Compositions and Methods of Use
#506Genetic products differentially expressed in tumors and the use thereof
#507Neuropilin antagonists
#508TUSC2 THERAPIES
#509Antibodies for epidermal growth factor receptor 3 (HER3)
#510Fully human antibodies specific to CADM1
#511Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
#512Non-functional P2Xreceptor
#513PTA089 PROTEIN
#514TUMOR MARKERS AND METHODS OF USE THEREOF
#515METHODS OF IMPROVING THE THERAPEUTIC EFFICACY AND UTILITY OF ANTIBODY FRAGMENTS
#516Genetic products differentially expressed in tumors and use thereof
#517Antibodies to endoplasmin and their use
#518Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
#519Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma
#520Anti-human CLCP1 antibody and use thereof
#521Neoplasm specific antibodies and uses thereof
#522Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
#523Neuropilin antagonists
#524Humanized monoclonal antibodies and methods of use
#525EBI3, DLX5, NPTX1 AND CDKN3 FOR TARGET GENES OF LUNG CANCER THERAPY AND DIAGNOSIS
#526Compositions and methods for the diagnosis and treatment of tumor
#527Survivin, a protein that inhibits cellular apoptosis, and its modulation
#528Non-functional P2Xreceptor
#529Method of treating solid cancers with pegylated IL-10
#530EXPRESSION PROFILING PLATFORM TECHNOLOGY
#531Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
#532LUCA2 and Antibodies That Bind Thereto
#533Antibodies to interleukin-6
#534LM-1 ANTIBODIES, FUNCTIONAL FRAGMENTS, LM-1 TARGET ANTIGEN, AND METHODS FOR MAKING AND USING SAME
#535Compositions and methods for diagnosing and treating cancer
#536Compositions and methods for the diagnosis and treatment of tumor
#537CANCER ASSOCIATED GENE LY6K
#538COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
#539Antibody-based therapeutics with enhanced ADCC activity
#540HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES
#541Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
#542Frizzled-binding agents and uses thereof
#543ANTIBODIES AGAINST A PROTEIN ENTITLED 161P2F10B
#544PROTEINS
#545PROTEINS
#546Protein
#547HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES
#548Compositions and methods for the diagnosis and treatment of tumor
#549Compositions and methods for the diagnosis and treatment of tumor
#550SRA binding protein
#551Compositions and methods for the diagnosis and treatment of tumor
#552Modified aerolysin and methods of use for treating lung cancer
#553Pro104 antibody compositions and methods of use
#554USE OF PEGYLATED IL-10 TO TREAT CANCER
#555Genetic products differentially expressed in tumors and the use thereof
#556Non-functional P2Xreceptor
#557Genetic products differentially expressed in tumors and the use of thereof
#558Compositions and Methods for the Diagnosis and Treatment of Tumor
#559CANCEROUS DISEASE MODIFYING ANTIBODIES
#560Cytotoxicity mediation of cells evidencing surface expression of MCSP
#561Compositions and methods for the diagnosis and treatment of tumor
#562Genetic products differentially expressed in tumors and use thereof
#563GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND USE THEREOF
#564Cancer vaccine
#565CANCEROUS DISEASE MODIFYING ANTIBODIES
#566Compositions and methods for the therapy and diagnosis of lung cancer
#567Cytotoxicity mediation of cells evidencing surface expression of CD63
#568Cytotoxicity mediation of cells evidencing surface expression of CD59
#569Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLS)
#570Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC)
#571Cancerous disease modifying antibodies
#572Cancerous disease modifying antibodies
#573COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
#574Methods for Treating Cancer Using Agents That Inhibit Wnt16 Signaling
#575Cytotoxicity mediation of cells evidencing surface expression of MCSP
#576Compositions and methods for the diagnosis and treatment of tumor
#577Molecular Markers Associated with Bone Metastasis
#578Neuropilin antagonists
#579Cancerous disease modifying antibodies
#580Anti-human DLL4 antibodies and compositions
#581COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
#582COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
#583Antibodies to non-functional P2Xreceptor
#584Antibody
#585Use of Pegylated IL-10 to Treat Cancer
#586Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
#587Lng105 Antibody Composition and Methods of Use, and Use of Lng105 to Assess Lung Cancer Risk
#588Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
#589TAT-030 and methods of assessing and treating cancer
#590TAT-031 and methods of assessing and treating cancer
#591Methods of treating cancer comprising administering an interleukin-6 antibody variable region
#592Alpha-enolase specific antibody and method of use
#593Bifunctional energy-reversible acyl-compositions
#594Compositions and methods for the therapy and diagnosis of lung cancer
#595Antibody-based therapeutics with enhanced ADCC activity
#596Pro104 antibody compositions and methods of use
#597Compositions and Methods for the Diagnosis and Treatment of Tumor
#598Cancer specific monoclonal antibodies
#599Detection and treatment of cancers of the lung
#600Anticarcinoma antibodies and uses thereof